Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
about
Exenterative surgery for recurrent gynaecological malignanciesExenterative surgery for recurrent gynaecological malignanciesHormonal therapy in advanced or recurrent endometrial cancerCancer of the endometrium: current aspects of diagnostics and treatmentPast, present, and future of hormonal therapy in recurrent endometrial cancerSERPINA3 promotes endometrial cancer cells growth by regulating G2/M cell cycle checkpoint and apoptosis.Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?Expression of monocyte chemotactic protein-1 in human endometrial cancer cells and the effect of treatment with tamoxifen or buserelin.Fulvestrant for the treatment of endometrial cancer.Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group studyFOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer.Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective studyPhase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.Treatment for advanced and recurrent endometrial carcinoma: combined modalities.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growthIntegrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and guide drug discovery.Current treatment of metastatic endometrial cancer.G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growthComparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer.Medical therapy of endometrial cancer: current status and promising novel treatments.An update on the pharmacotherapy for endometrial cancer.Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.Regulation of epithelial-mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs.Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsPromotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue.Clinical Behavior and Treatment of Endometrial Cancer.The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
P2860
Q24200357-ED67A770-AF8A-4439-88EF-009FF6C33FBAQ24200596-EEF72BB1-F008-45F8-98D9-9BE4EEA5D544Q24235543-327F67AC-0143-446E-9403-97EFFE43883AQ24797130-52AF8516-C876-42DE-9B54-8AF6A718FFEEQ26993208-D24CDF88-355F-4060-B555-02F883F0571BQ33582882-8B23AAFC-7261-4F9A-ABA6-3A6E9309B53CQ33633962-9B65D4F5-FA48-484A-A264-C32F4C91A234Q33997896-C996EFF7-D94F-4BB7-9C8D-8B708F4AB3EFQ34514391-C437E92A-DC7A-4FA8-987D-F787F084E672Q34571141-EBC3E9DA-F815-419E-BF68-9A84DD648CAAQ35023418-6026D881-8A84-406B-ABCD-B0DAB34C64FDQ35089958-8C823351-B8BE-441E-9B36-4F865ABD8287Q35103319-74D88369-AA1A-4B7D-ADB3-C08BFB1ED886Q35172203-9FC1D759-D78E-4F13-A612-32E72F7DBAFBQ35584242-392DA831-4AC1-4C0C-8B6B-479D0FDDC9FDQ36372293-6AC6D0FF-502D-492D-966D-C1BC15653E54Q36407018-CD897BAF-75A1-4917-9950-06D1538F5DC8Q36886180-8D1AF1A1-2F9F-48D2-8E10-40B781D789E3Q36905799-056C5787-9BF5-4E19-B630-41DDD74C747CQ37349633-8C4DED94-545D-4453-B292-D3626B1AC505Q37393019-A1B2908F-0E1E-42D0-B2B6-3373E5067010Q37401603-73259BF7-39AB-461D-8722-3C597A8CB4C7Q37996079-ED0870AB-B5FB-483A-BA62-F1EA81172E44Q38153754-F8DDE7D9-FEF6-431E-9C0C-FA41D5A71094Q38203354-9EDC2B4C-8630-4F86-86C0-37B917AA8F57Q38726364-5DE4E258-5738-4AAD-B1FC-D6621BD8BBCAQ38849896-5D1EF054-2D14-4E8D-8739-4F9AA9525CF3Q38895754-8D6A85E3-2520-454E-BA28-22A4D552F44DQ48332429-FFE1DB02-4076-423D-AB77-A9D1B8C77513Q54011680-70DEC0A8-267C-4631-BA57-1F1D27342C50Q54601832-D090EDFE-51FA-4DD2-B78E-D3DEC33839EAQ57903637-B7092F98-A97E-4DB8-8FF8-FF247A88E5B8
P2860
Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tamoxifen in the treatment of ...... ecologic Oncology Group study.
@ast
Tamoxifen in the treatment of ...... ecologic Oncology Group study.
@en
type
label
Tamoxifen in the treatment of ...... ecologic Oncology Group study.
@ast
Tamoxifen in the treatment of ...... ecologic Oncology Group study.
@en
prefLabel
Tamoxifen in the treatment of ...... ecologic Oncology Group study.
@ast
Tamoxifen in the treatment of ...... ecologic Oncology Group study.
@en
P2093
P1476
Tamoxifen in the treatment of ...... ecologic Oncology Group study.
@en
P2093
P304
P356
10.1200/JCO.2001.19.2.364
P407
P577
2001-01-01T00:00:00Z